Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486787 | 1.00 | HTR6 (0.52) | HTR6PSIP1CA1CA2ALDH1A1 | |
| SCHEMBL486856 | 1.00 | HTR6 (0.52) | HTR6PSIP1CA1CA2ALDH1A1 | |
| SCHEMBL22116923 | 0.97 | HTR6 (0.50) | HTR6PSIP1CA1CA2ALDH1A1 | |
| Methylphenylsulfone SCHEMBL1332357 | 0.77 | PTGS2 (0.62) | HTR6PSIP1CA1CA2ALDH1A1 | |
| SCHEMBL2285511 | 0.77 | HTR6 (0.58) | HTR6PSIP1CA1CA2ALDH1A1 | |
| Methylphenylsulfone SCHEMBL78253 | 0.77 | PTGS2 (0.62) | HTR6PSIP1CA1CA2ALDH1A1 | |
| SCHEMBL488382 | 0.76 | GAA (0.59) | CA1CA2ALDH1A1TDP1CA12 | |
| (Phenylsulfonyl)Benzene SCHEMBL10870153 | 0.74 | HTR6 (0.82) | HTR6PSIP1CA1CA2ALDH1A1 | |
| Methylphenylsulfone SCHEMBL5499087 | 0.74 | PTGS2 (0.60) | HTR6PSIP1CA1CA2ALDH1A1 | |
| SCHEMBL23145865 | 0.74 | ENPP2 (0.41) | CA1CA2CA12CA3CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503446-B2 | Bromodomain inhibitors | Forschungszentrum Jülich GmbH (DE) | 2025-12-23 | — | — | US | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-20220372004-A1 | BROMODOMAIN INHIBITORS | Forschungszentrum Jülich GmbH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021135938-A1 | HETEROCYCLIC SULFOXIMINE COMPOUND AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 南京创济生物医药有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| WO-2021083879-A1 | BROMODOMAIN INHIBITORS | RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) | 2021-05-06 | — | — | WO | disclosed |
| US-10981911-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| EP-2152672-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-17 | — | — | EP | disclosed |
| EP-2099757-A2 | SULFOXIMINES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYTOCHROMA INC. (CA) | 2006-09-28 | — | — | US | disclosed |
| US-7101865-B2 | 24-sulfoximine vitamin D3 compounds | CYTOCHROMA INC. (CA) | 2006-09-05 | — | — | US | disclosed |
| EP-1511725-A1 | 24-SULFOXIMINE VITAMIN D sb 3 /sb COMPOUNDS | Johns Hopkins University (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038949-A1 | 24-sulfoximine vitamin D3 compounds | JOHNS HOPKINS UNIVERSITY | 2004-02-26 | — | — | US | disclosed |
| WO-2003106411-A1 | 24-SULFOXIMINE VITAMIN D3 COMPOUNDS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | HTR6 2827/4885PSIP1 867/4885CA1 4821/4885 |
| US-20040038949-A1 | 24-sulfoximine vitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | HTR6 3037/4885PSIP1 1611/4885CA1 3379/4885 |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JAK1, JAK2, JAK3 | HTR6 2827/4885PSIP1 867/4885CA1 4821/4885 |
| US-10981911-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | HTR6 2827/4885PSIP1 867/4885CA1 4821/4885 |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K2 | HTR6 1886/4885PSIP1 3383/4885CA1 4102/4885 |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | HTR6 2945/4885PSIP1 1472/4885CA1 3533/4885 |
| US-20220372004-A1 | BROMODOMAIN INHIBITORS | BRDT, BRD4, BRPF3 | HTR6 3390/4885PSIP1 3259/4885CA1 4251/4885 |
| US-12503446-B2 | Bromodomain inhibitors | BRDT, BRD4, BRPF3 | HTR6 3390/4885PSIP1 3259/4885CA1 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.